GlaxoSmithKline plc (GSK) announced today that the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for the once-daily use of Promacta® (eltrombopag) in patients with severe aplastic anaemia (SAA) who have had an insufficient response to immunosuppressive therapy (IST).

Merck announced final results from a Phase III, open-label study designed to compare the impact of two anemia management strategies on sustained virologic response ( SVR ) in patients with chronic hepatitis C virus ( HCV ) genotype 1 infection treated with VICTRELIS  ( boceprevir ) in combination with PEGINTRON  ( peginterferon alfa-2b ) and ribavirin (P/R).

Results from THALASSA , the first pivotal placebo-controlled study examining the benefit of iron chelation with Exjade ( deferasirox ) in patients with non-transfusion-dependent thalassemia ( NTDT ), show that Exjade can significantly reduce iron overload. These data were presented at the 53rd Annual Meeting of the American Society of Hematology in San Diego.